Highlights

• FPH rose 1.19% to $36.66 on 4 September 2026

• Full-year FY2026 results reported for the year ended 31 March 2026

• 462,365 employee Options lapsed in September after vesting conditions were not met

• FY2026 full-year report and financial presentations released to investors

Fisher & Paykel Healthcare Corporation Ltd (ASX:FPH) added 1.19% to reach $36.66 on 4 September 2026. The New Zealand-headquartered respiratory healthcare company has been an ASX standout, and today's gain follows the release of its full-year results and continued investor interest in its core respiratory and acute care product lines.

About the Company

Fisher & Paykel Healthcare is a world-leading designer and manufacturer of medical devices and systems for use in respiratory care, acute care, and the treatment of obstructive sleep apnoea. Headquartered in Auckland, New Zealand, the company sells its products in more than 120 countries and is known for its hospital respiratory humidification systems and innovative homecare products. FPH is dual-listed on the ASX and NZX and is considered a high-quality growth Business within the global medical device sector.

Key Developments

Fisher & Paykel Healthcare has reported its full-year FY2026 results for the year ended 31 March 2026. The company's investor materials include the FY2026 full-year report and financial presentations. In September 2026, the company also reported that 462,365 employee options had lapsed after specified vesting conditions were not met.

Key Catalysts to Watch

• Revenue growth momentum in hospital and homecare product lines

• Expansion into new international markets, particularly in Asia and North America

• Product innovation updates including next-generation respiratory devices

• Currency movements given significant USD and EUR Earnings exposure

Risks

• Competition from global medical device giants such as Philips and ResMed

• Currency risk given earnings in NZD but costs and revenues spread globally

• Potential disruption to hospital procurement cycles

• Options lapsing may indicate performance targets are proving harder to achieve

Conclusion

Fisher & Paykel Healthcare continues to be regarded as one of the premium quality medical device businesses listed on the ASX. The FY2026 full-year result has been released and investors are looking to new-product momentum and international expansion to sustain earnings growth. The lapsing of employee options is a minor note but worth monitoring for future retention signals. Today's 1.19% gain reflects ongoing market confidence in FPH's Long-term Growth runway.